GENE THERAPY IN HEART FAILURE FORTHCOMING THERAPIES

31. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B,Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ: Calcium Upregulation byPercutaneous Administration of Gene Therapy in Cardiac Disease(CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcopl[r]

CHẨN ĐOÁN, ĐIỀU TRỊ & DIỄN TIẾN LÂM SÀNG SUY TIM CÓ PHÂNSUẤT TỐNG MÁU BẢO TỒN TẠI BV TIM MẠCH AN GIANG 4-10/2013BS Bùi Hữu Minh Trí, BS Dương Hồng Chương, BS Trương Hữu Có, BS Đỗ Minh Tới,BS Nguyễn Thị Tuyết, BS Trương Thu HươngTÓM TẮTMục tiêu: Xác định đặc điểm BN chẩn đoán suy tim phân suấ[r]

Pre-PCI3 Months Pre-PCILVEF improved from visual estimate 20% to 40%Myocardial Revascularisation In Chronic Heart Failure• Coronary artery disease remains the most common cause of CHF• Patients with depressed LV function remain ar risk of sudden cardiac deathwith or without reva[r]

ACUTE DECOMPENSATED HEART FAILURE 1/10/2015 SUY TIM M [”Clinical assessment of heart failure.Diagnosis and Management of Acute Heart Failure”: Braunwalds heart disease. 10th 2015: 473-511. ACCF/AHA (201[r]

it also operates locally. Intrarenally produced AII contributes to glomerular efferent arteriolar constriction, and this "tubuloglomerular feedback" causes salt and water retention. These renal effects of AII are mediated by activation of AII type 1 receptors, which can be blocked by specific antago[r]

receiving ACE-I due to a history of intolerance [47]. Therewas a statistically significant reduction in cardiovasculardeath and hospital admission for CHF among patientstreated with candesartan compared to those treated withplacebo. This suggests that ARB’s may be a good alternative to ACE-I’[r]

The long held belief that pregnancy is absolutely contraindi-cated in maternal cardiovascular diasease is no longer justifi able using evidenced - based medicine. There are some conditions in which pregnancy is contraindicated and a high maternal risk and poor fetal outcome can be predi[r]

Anti-PD-1 and BRAF-inhibitors (BRAFi) have been approved as first-line treatments in advanced melanoma. To date, no prospective data are available to give the best sequence of treatment.

Hajjar RJ: Restoration of mechanical and energetic function in failingaortic-banded rat hearts by gene transfer of calcium cycling proteins. JMol Cell Cardiol 2007, 42:852-861.17. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R,Hoshino K, Takewa Y, Sakata S, Pe[r]

Chapter 036. Edema (Part 7) Additional Factors in Diagnosis The color, thickness, and sensitivity of the skin are significant. Local tenderness and warmth suggest inflammation. Local cyanosis may signify venous obstruction. In individuals who have had repeated episodes of prolonged e[r]

the activity of the oxidation-sensitive transcription factor NFk-B, may be a usefulapproach. NFk-B is linked to the expression of a number of proinflammatory genes.It inhibition succeeded in reducing infarct size after coronary artery ligation.Genetic manipulation of donor tissues offers the o[r]

Chapter 065. Gene Therapy in Clinical Medicine (Part 3) Long-Term Expression in Genetic Disease: In Vivo Gene Transfer with Recombinant Adeno-Associated Viral (AAV) Vectors Recombinant AAV vectors have emerged as attractive gene delivery vehicles for[r]

CAUSES AND SYMPTOMS The most common causes of heart failure are: • coronary artery disease and heart attack which may be "silent" • cardiomyopathy • high blood pressure hypertension • he[r]

endocrine therapies; however, combination endocrine therapies do not appear to be superior to individual agents, and combinations of chemotherapy with endocrine therapy are not useful. The median survival of patients with metastatic disease is approximately 2 years, and many pat[r]